YS

YS Biopharma Co Ltd
NASDAQ
0.7950
-0.0150
-1.85%
Closed 16:00 04/25 EDT
OPEN
0.8100
PREV CLOSE
0.8100
HIGH
0.8500
LOW
0.7111
VOLUME
69.82K
TURNOVER
0
52 WEEK HIGH
1.970
52 WEEK LOW
0.3503
MARKET CAP
149.72M
P/E (TTM)
-3.0946
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at YS last week (0415-0419)?
Weekly Report · 3d ago
YS Biopharma reports 9M results
Seeking Alpha · 6d ago
YS Stock Earnings: YS Biopharma Co Misses EPS, Beats Revenue for Q3 2024
YS Biopharma Co reported earnings per share of -12 cents for the third quarter of 2024. The company reported revenue of $23.82 million. This was 4.27% better than the analyst estimate of $22.84 million for the same period.
Investorplace · 6d ago
YS Biopharma Co Ltd: Report of foreign issuer
Press release · 04/18 16:01
YS BIOPHARMA CO LTD - PREPARING TO INITIATE A PHASE I CLINICAL TRIAL FOR YS-HBV-002 IN PHILIPPINES, WHICH IS EXPECTED TO BEGIN IN JUNE 2024
Reuters · 04/18 12:00
Weekly Report: what happened at YS last week (0408-0412)?
Weekly Report · 04/15 11:04
Chinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor
YS Biopharma has announced interim results from the ongoing Phase 3 clinical trial of its next-generation PIKA Rabies Vaccine. The company says the vaccine can potentially meet the WHO's goal of a one-week rabies vaccine regimen. The FDA has granted the vaccine orphan drug designation for rabies.
Benzinga · 04/09 19:30
YS Biopharma Co Ltd: Report of foreign issuer
Press release · 04/09 14:00
More
About YS
YS Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.

Webull offers YS Biopharma Co Ltd stock information, including NASDAQ: YS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading YS stock methods without spending real money on the virtual paper trading platform.